JP2012532899A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532899A5
JP2012532899A5 JP2012519900A JP2012519900A JP2012532899A5 JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5 JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5
Authority
JP
Japan
Prior art keywords
het
conr
hal
atoms
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519900A
Other languages
English (en)
Japanese (ja)
Other versions
JP5681182B2 (ja
JP2012532899A (ja
Filing date
Publication date
Priority claimed from DE102009033208A external-priority patent/DE102009033208A1/de
Application filed filed Critical
Publication of JP2012532899A publication Critical patent/JP2012532899A/ja
Publication of JP2012532899A5 publication Critical patent/JP2012532899A5/ja
Application granted granted Critical
Publication of JP5681182B2 publication Critical patent/JP5681182B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519900A 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体 Expired - Fee Related JP5681182B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009033208.1 2009-07-15
DE102009033208A DE102009033208A1 (de) 2009-07-15 2009-07-15 Aminopyridinderivate
PCT/EP2010/003659 WO2011006567A1 (de) 2009-07-15 2010-06-17 Aminopyridinderivate zur behandlung von tumoren und entzündungskrankheiten

Publications (3)

Publication Number Publication Date
JP2012532899A JP2012532899A (ja) 2012-12-20
JP2012532899A5 true JP2012532899A5 (enExample) 2013-08-29
JP5681182B2 JP5681182B2 (ja) 2015-03-04

Family

ID=42665826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519900A Expired - Fee Related JP5681182B2 (ja) 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体

Country Status (11)

Country Link
US (1) US8648201B2 (enExample)
EP (1) EP2454253B1 (enExample)
JP (1) JP5681182B2 (enExample)
CN (1) CN102471317B (enExample)
AR (1) AR077567A1 (enExample)
AU (1) AU2010272920B2 (enExample)
CA (1) CA2768169C (enExample)
DE (1) DE102009033208A1 (enExample)
ES (1) ES2534095T3 (enExample)
IL (1) IL217467A (enExample)
WO (1) WO2011006567A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010233917B2 (en) * 2009-04-02 2015-07-02 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
JP2013510824A (ja) * 2009-11-12 2013-03-28 セルビタ エス.エー. セリン/トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン/トレオニンキナーゼ調節剤
JP5690839B2 (ja) * 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
KR20140014205A (ko) * 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
EP2736330A4 (en) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
EP2802577B1 (en) * 2012-01-13 2017-03-01 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104662014B (zh) * 2012-07-10 2017-02-22 阿雷斯贸易股份有限公司 嘧啶吡唑基衍生物
EP2903613B1 (en) * 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
EP2903617B1 (en) 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US20160166576A1 (en) 2013-07-11 2016-06-16 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
WO2016038540A1 (en) * 2014-09-11 2016-03-17 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN112457308B (zh) * 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
CA3196620A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
KR20250016079A (ko) * 2022-03-02 2025-02-03 항저우 바이오-신세리티 파마-테크 컴퍼니 리미티드 히스타민 h3 수용체 길항제 및 이의 약학적 용도
CN121646587A (zh) * 2024-05-30 2026-03-10 深圳微芯生物科技股份有限公司 一种苯并咪唑类化合物、其制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
KR20040084896A (ko) * 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Gsk-3의 억제제로서 유용한 헤테로아릴 화합물
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
JP2006516626A (ja) * 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
WO2009005337A1 (en) 2007-06-29 2009-01-08 Vekoma Rides Engineering B.V. Amusement device seat assembly
WO2009024825A1 (en) * 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
KR100979439B1 (ko) 2008-04-10 2010-09-02 한국화학연구원 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2012532899A5 (enExample)
JP2012506389A5 (enExample)
JP2014520767A5 (enExample)
JP2014508811A5 (enExample)
JP2011530545A5 (enExample)
JP2010529051A5 (enExample)
JP2012092103A5 (enExample)
JP2010532768A5 (enExample)
JP2014508753A5 (enExample)
JP2012111953A5 (enExample)
JP2010526025A5 (enExample)
JP2015536947A5 (enExample)
JP2010095546A5 (enExample)
JP2009529540A5 (enExample)
HRP20161103T1 (hr) Kemijski spojevi
JP2013542218A5 (enExample)
AR078497A1 (es) Isoxazoles como antagonistas de los receptores de acido lisofosfatidico
RU2018116351A (ru) Пиримидиновое соединение
JP2018533593A5 (enExample)
JP2009501198A5 (enExample)
JP2012506896A5 (enExample)
JP2010510177A5 (enExample)
JP2015522650A5 (enExample)
JP2013521295A5 (enExample)
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias